Apeiron announces start of phase I trail with cellular anti cancer therapy
The trial studies the safety, tolerability and optimal dose of autologous, peripheral immune cells silenced ex-vivo for the Cbl-b gene, a completely novel approach to support the immune system’s ability to fight cancer via checkpoint blockade.
“There are factors in immune cells that hamper their ability to efficiently kill cancer cells. Achieving a so-called ‘checkpoint blockade’ by treating certain blood derived immune cells ex-vivo with a small interfering ribonucleic acid (siRNA) to silence the Cbl-b gene helps those cells to more efficiently kill cancer cells after re-infusion," said Pierre L. Triozzi. “Such activation of the immune system could in principle be applied for treatment of any type of cancer, and also in combination with other immunotherapies such as other checkpoint blockades or cancer vaccination approaches,” he added.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.